<?xml-stylesheet type='text/xsl' href='ctgovTransform.xsl'?>
<CT.GOV_Trial requestNumber="5876">
  <stage>Registered</stage>
  <submitdate>21/08/2015</submitdate>
  <approvaldate>21/08/2015</approvaldate>
  <nctid>NCT02532283</nctid>
  <trial_identification>
    <studytitle>A Study to Evaluate the Pharmacokinetics, Safety, and Antiviral Activity of JNJ-63623872 in Combination With Oseltamivir in Adult, and Elderly Hospitalized Participants With Influenza A Infection</studytitle>
    <scientifictitle>A Phase 2, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Pharmacokinetics, Safety, and Antiviral Activity of JNJ-63623872 in Combination With Oseltamivir in Adult and Elderly Hospitalized Patients With Influenza A Infection</scientifictitle>
    <utrn />
    <trialacronym />
    <secondaryid>2015-003002-17</secondaryid>
    <secondaryid>CR107746</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Influenza A Virus</healthcondition>
  </conditions>
  <interventions>
    <interventions>Treatment: drugs - JNJ-63623872
Treatment: drugs - Placebo
Treatment: drugs - Oseltamivir

Experimental: JNJ-63623872 plus Oseltamivir - Participants will be administered JNJ-63623872 600 milligram (mg) tablets and oseltamivir 75 mg capsules orally twice daily for 7 days.

Experimental: Placebo plus Oseltamivir - Participants will be administered placebo tablets and oseltamivir 75 mg capsules orally twice daily for 7 days.


Treatment: drugs: JNJ-63623872
Participants will be administered JNJ-63623872 600 milligram (mg) tablets orally twice daily for 7 days.

Treatment: drugs: Placebo
Participants will be administered placebo tablets orally twice daily for 7 days.

Treatment: drugs: Oseltamivir
Participants will be administered oseltamivir 75 mg capsules orally twice daily for 7 days.

</interventions>
    <comparator />
    <control />
    <interventioncode>Treatment: drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Trough Plasma Concentration (Ctrough) of JNJ-63623872 - The Ctrough is the plasma concentration before dosing or at the end of the dosing interval of any dose other than the first dose in a multiple dosing regimen.</outcome>
      <timepoint>Pre-dose, 1.5, 6 and 12 hours post-dose on Day 1; Pre-dose, 1.5 and 6 hours post-dose on Day 2 and 4 to 7; Pre-dose, 1, 2, 4, 6, 8, 10 and 12 hours post-dose on Day 3</timepoint>
    </primaryOutcome>
    <primaryOutcome>
      <outcome>Minimum Observed Plasma Concentration (Cmin) of JNJ-63623872 - The Cmin is the minimum observed plasma concentration.</outcome>
      <timepoint>Pre-dose, 1.5, 6 and 12 hours post-dose on Day 1; Pre-dose, 1.5 and 6 hours post-dose on Day 2 and 4 to 7; Pre-dose, 1, 2, 4, 6, 8, 10 and 12 hours post-dose on Day 3</timepoint>
    </primaryOutcome>
    <primaryOutcome>
      <outcome>Maximum Observed Plasma Concentration (Cmax) of JNJ-63623872 - The Cmax is the maximum observed plasma concentration.</outcome>
      <timepoint>Pre-dose, 1.5, 6 and 12 hours post-dose on Day 1; Pre-dose, 1.5 and 6 hours post-dose on Day 2 and 4 to 7; Pre-dose, 1, 2, 4, 6, 8, 10 and 12 hours post-dose on Day 3</timepoint>
    </primaryOutcome>
    <primaryOutcome>
      <outcome>Time to Reach Maximum Observed Plasma Concentration (Tmax) of JNJ-63623872 - The Tmax is defined as actual sampling time to reach maximum observed concentration of JNJ-63623872.</outcome>
      <timepoint>Pre-dose, 1.5, 6 and 12 hours post-dose on Day 1; Pre-dose, 1.5 and 6 hours post-dose on Day 2 and 4 to 7; Pre-dose, 1, 2, 4, 6, 8, 10 and 12 hours post-dose on Day 3</timepoint>
    </primaryOutcome>
    <primaryOutcome>
      <outcome>Area Under the Plasma Concentration-Time Curve From Time of Administration to 12 hours After Dosing (AUC [0-12]) - The AUC(0-12) is the area under the plasma concentration-time curve from time zero to 12 hours.</outcome>
      <timepoint>Pre-dose, 1.5, 6 and 12 hours post-dose on Day 1; Pre-dose, 1.5 and 6 hours post-dose on Day 2 and 4 to 7; Pre-dose, 1, 2, 4, 6, 8, 10 and 12 hours post-dose on Day 3</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Time to Influenza Viral Negativity - Time to influenza viral negativity will be measured based on quantitative reverse transcription polymerase chain reaction (qRT-PCR) and/or viral culture from nasal mid-turbinate (MT) swabs and, if applicable, based on PCR-based rapid molecular testing from nasal MT swabs.</outcome>
      <timepoint>Up to Day 28</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Viral Load Over Time - Viral load over time will be measured by qRT-PCR and/or viral culture.</outcome>
      <timepoint>Up to Day 28</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Rate of Decline in Viral Load - Rate of decline in viral load during treatment as measured by qRT-PCR and/or viral culture.</outcome>
      <timepoint>Up to Day 28</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Area Under the Plasma Concentration-Time Curve (AUC) of Viral Load - The AUC of viral load as measured by qRT-PCR and/or viral culture.</outcome>
      <timepoint>Up to Day 28</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Disease Status and Incidence of Complications Associated With Influenza - Disease status and incidence of complications associated with influenza are: bacterial pneumonia (culture confirmed where possible), other bacterial superinfections, respiratory failure, pulmonary disease (example, asthma, chronic obstructive pulmonary disease [COPD]), cardiovascular and cerebrovascular disease (example, myocardial infarction, congestive heart failure [CHF], arrhythmia, stroke).</outcome>
      <timepoint>Up to Day 28</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Change in Duration and Severity of Clinical Symptoms - Change in duration and severity of clinical symptoms as measured by the Flu-iiQ (intensity and impact questionnaire) questionnaires.</outcome>
      <timepoint>Up to Day 28</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Time to Improvement of Vital Signs - Vital signs include systolic blood pressure [SBP], diastolic blood pressure [DBP], pulse rate, respiratory rate, and body temperature.</outcome>
      <timepoint>Up to Day 28</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Time to Improvement of Respiratory Status - Time to improvement of respiratory status is defined as normalization of blood oxygen saturation and respiration rate.</outcome>
      <timepoint>Up to Day 28</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Emergence of Drug Resistance - Emergence of drug resistance will be detected by genotype or phenotype.</outcome>
      <timepoint>Up to Day 28</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Time to Return to Premorbid Functional Status - Time to return to premorbid functional status will be evaluated.</outcome>
      <timepoint>Up to Day 28</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Time to Hospital Discharge - Time to hospital discharge in days will be analyzed using an accelerated failure time model (if the data provide an acceptable model fit) or alternatively a Cox proportional hazards model (in case the hazards are proportional).</outcome>
      <timepoint>Up to Day 28</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Time to Significant Reduction in Influenza Symptom Severity - Time to reduction in influenza symptom severity will be measured.</outcome>
      <timepoint>Up to Day 28</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Percentage of Participants With a Significant Reduction to Mild or None for all Influenza Symptoms at Each Assessment - Participants with a significant reduction to mild or none for all influenza symptoms at each assessment will be analysed.</outcome>
      <timepoint>Up to Day 28</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Number of Participants with Adverse Events (AEs) and Serious AEs - An adverse event (AE) is any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. A serious adverse event (SAE) is an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly.</outcome>
      <timepoint>Screening up to follow-up (21 days after last dose administration)</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Participants Improvement on Ordinal Scale - The ordinal scale will be used to assess participant's status and consists of 6 categories or clinical states that are exhaustive, mutually exclusive, and ordered, where 1- Death, 2- Admitted to ICU or mechanically ventilated/ extracorporeal membrane oxygenation (ECMO), 3- Non-ICU plus supplemental oxygen, 4- Non-ICU plus no supplemental oxygen, 5- Not hospitalized, but unable to continue activity, 6- Not hospitalized and continues activities.</outcome>
      <timepoint>Up to Day 28</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>-  Participant requires hospitalization to treat influenza infection and/or to treat
             complications of influenza infection

          -  Participant tested positive for influenza A infection within 1 day of signing of the
             informed consent form (ICF)/assent form using a polymerase chain reaction (PCR)-based
             rapid molecular diagnostic assay

          -  Participants must be capable of swallowing study medication tablets and capsules

          -  Each participant (or their legally acceptable representative) must sign an ICF
             indicating that he or she understands the purpose of and procedures required for the
             study and is willing to participate in the study

          -  Participant must be willing and able to adhere to the prohibitions and restrictions
             specified in the protocol</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>85</inclusivemaxage>
    <inclusivemaxagetype>Years</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>-  Participant received more than 3 doses of the influenza antiviral medication
             oseltamivir, zanamivir, or peramivir since the start of the influenza symptoms, or
             ribavirin within 6 months prior to Screening

          -  Participant is unwilling to undergo regular nasal Mid-turbinate (MT) swabs or has any
             physical abnormality which limits the ability to collect regular nasal specimens

          -  Participant is immunocompromised, whether due to underlying medical condition
             (example, malignancy) or medical therapy (example, medications, chemotherapy,
             radiation, post-transplant)

          -  Participant is undergoing peritoneal dialysis, hemodialysis, or hemofiltration

          -  Participant has an estimated glomerular filtration rate (eGFR) less than or equal to
             (&lt;=)30 milliliter (mL)/minute (min)/1.73 meter^2 (m^2) according to the Modification
             of Diet in Renal Disease (MDRD) equation, assessed at Screening or based on the most
             recent clinically relevant creatinine value if available</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment />
    <sequence />
    <masking>Blinded (masking used)</masking>
    <assignment>Parallel</assignment>
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1>The people receiving the treatment/s</masking1>
    <masking2 />
    <masking3 />
    <masking4>The people analysing the results/data</masking4>
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 2</phase>
    <anticipatedstartdate />
    <actualstartdate>11/12/2015</actualstartdate>
    <anticipatedenddate />
    <actualenddate />
    <samplesize />
    <actualsamplesize>102</actualsamplesize>
    <recruitmentstatus>Completed</recruitmentstatus>
    <anticipatedlastvisitdate />
    <actuallastvisitdate>15/03/2017</actuallastvisitdate>
    <dataanalysis />
    <withdrawnreason />
    <withdrawnreasonother />
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate />
    <hospital> - Cairns</hospital>
    <hospital> - Parkville</hospital>
    <hospital> - South Brisbane</hospital>
    <hospital> - Westmead</hospital>
    <postcode> - Cairns</postcode>
    <postcode> - Parkville</postcode>
    <postcode> - South Brisbane</postcode>
    <postcode> - Westmead</postcode>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>California</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Florida</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Illinois</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Michigan</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Minnesota</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Missouri</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>New Jersey</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>North Carolina</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Texas</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Belgium</country>
      <state>Aalst</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Belgium</country>
      <state>Bruxelles</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Belgium</country>
      <state>Leuven</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Brazil</country>
      <state>Passo Fundo</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Brazil</country>
      <state>Porto Alegre</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Brazil</country>
      <state>Sao Paulo</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Canada</country>
      <state>Ontario</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Canada</country>
      <state>Quebec</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>France</country>
      <state>Dijon</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>France</country>
      <state>Grenoble</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>France</country>
      <state>Limoges</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>France</country>
      <state>Lyon</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>France</country>
      <state>Nantes</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>France</country>
      <state>Paris</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>France</country>
      <state>Poitiers</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>France</country>
      <state>Rennes</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>France</country>
      <state>Saint-Priest En Jarez</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>France</country>
      <state>Tours Cedex 9</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Donaustauf</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Jena</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Hong Kong</country>
      <state>Hong Kong</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Malaysia</country>
      <state>Kota Bharu</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Malaysia</country>
      <state>Kuala Lumpur</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Malaysia</country>
      <state>Kuala</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Malaysia</country>
      <state>Kuching</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Malaysia</country>
      <state>Melaka</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Malaysia</country>
      <state>Miri</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Malaysia</country>
      <state>Sungai Buloh</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Malaysia</country>
      <state>Taiping</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Netherlands</country>
      <state>Rotterdam</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Netherlands</country>
      <state>Utrecht</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Netherlands</country>
      <state>Zutphen</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>New Zealand</country>
      <state>Hamilton</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Singapore</country>
      <state>Singapore</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Spain</country>
      <state>Alicante</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Spain</country>
      <state>Barcelona</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Spain</country>
      <state>Bizkaia</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Spain</country>
      <state>Elche</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Spain</country>
      <state>Granada</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Spain</country>
      <state>Madrid</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Spain</country>
      <state>Mataró</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Spain</country>
      <state>San Sebastián</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Spain</country>
      <state>Vigo</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Sweden</country>
      <state>Malmö</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Sweden</country>
      <state>Umeå</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Sweden</country>
      <state>Uppsala</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Turkey</country>
      <state>Ankara</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Turkey</country>
      <state>Eskisehir</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Turkey</country>
      <state>Istanbul</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Turkey</country>
      <state>Izmir</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Turkey</country>
      <state>Trabzon</state>
    </countryoutsideaustralia>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Commercial sector/Commercial sector/Industry</primarysponsortype>
    <primarysponsorname>Janssen Research &amp; Development, LLC</primarysponsorname>
    <primarysponsoraddress />
    <primarysponsorcountry />
  </sponsorship>
  <ethicsAndSummary>
    <summary>The purpose of this study is to evaluate the Pharmacokinetic parameters of JNJ-63623872 in
      combination with oseltamivir in elderly participants (aged 65 to &lt;= 85 years) compared to
      adults (aged 18 to &lt;= 64 years) with influenza A infection.</summary>
    <trialwebsite>https://clinicaltrials.gov/show/NCT02532283</trialwebsite>
    <publication />
    <ethicsreview />
    <publicnotes />
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Janssen Research &amp; Development, LLC Clinical Trial</name>
      <address>Janssen Research &amp; Development, LLC</address>
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Public Queries</type>
    </contact>
  </contacts>
</CT.GOV_Trial>